SCHEMBL19974773

SCHEMBL19974773

COc1ccccc1NC(=O)C(O)C(C)N(C=O)c1ccccc1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
LPAR1 Q92633 1/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
MAPT P10636 4/20 0.45
TSHR P16473 3/20 0.44
USP2 O75604 1/20 0.44
ALDH1A1 P00352 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C19 P33261 1/20 0.44
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
LMNA P02545 1/20 0.43
ANPEP P15144 1/20 0.43
GAA P10253 1/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30062960 1.00 POLB (0.49) POLBLPAR1MEN1KMT2AMAPT
SCHEMBL19974770 1.00 POLB (0.49) POLBLPAR1MEN1KMT2AMAPT
SCHEMBL19975376 0.85 L3MBTL1 (0.40) POLBMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL21176264 0.84 HPGD (0.43) POLBLPAR1MEN1KMT2AALDH1A1
SCHEMBL19974842 0.81 KMT2A (0.43) POLBKMT2AMAPTALDH1A1CYP1A2
SCHEMBL19975357 0.80 POLB (0.45) POLBLPAR1MEN1KMT2AMAPT
SCHEMBL19975358 0.80 POLB (0.45) POLBLPAR1MEN1KMT2AMAPT
SCHEMBL19975415 0.79 HPGD (0.42) MAPTTSHRALDH1A1TDP1L3MBTL1
SCHEMBL19974976 0.78 TSHR (0.40) POLBMEN1KMT2ATSHRALDH1A1
SCHEMBL19975543 0.76 HPGD (0.49) MEN1KMT2ATSHRALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C POLB 833/4885LPAR1 44/4885MEN1 4331/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C POLB 617/4885LPAR1 62/4885MEN1 4361/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C POLB 833/4885LPAR1 44/4885MEN1 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.